Hyperimmune anti-COVID-19 IVIG (C-IVIG) treatment in severe and critical COVID-19 patients: A phase I/II randomized control trial

BACKGROUND: Hyperimmune anti-COVID-19 Intravenous Immunoglobulin (C-IVIG) is an unexplored therapy amidst the rapidly evolving spectrum of medical therapies for COVID-19 and is expected to counter the three most life-threatening consequences of COVID-19 including lung injury by the virus, cytokine s...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:EClinicalMedicine
Autori principali: Ali, Shaukat, Uddin, Syed Muneeb, Shalim, Elisha, Sayeed, Muneeba Ahsan, Anjum, Fatima, Saleem, Farah, Muhaymin, Sheikh Muhammad, Ali, Ayesha, Ali, Mir Rashid, Ahmed, Iqra, Mushtaq, Tehreem, Khan, Sadaf, Shahab, Faisal, Luxmi, Shobha, Kumar, Suneel, Arain, Habiba, Khan, Mujtaba, Khan, Abdul Samad, Mehmood, Hamid, Rasheed, Abdur, Jahangeer, Ashraf, Baig, SaifUllah, Quraishy, Saeed
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier 2021
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8177439/
https://ncbi.nlm.nih.gov/pubmed/34109306
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eclinm.2021.100926
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi